The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
7 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,951,621 in first-year total cost, median $224,900.
Most frequent study sections
- Special Emphasis Panel[ZCA1 SRLB-X (J1)]4
- Special Emphasis Panel[ZCA1 SRLB-X (O1)]3
Most frequent institutions
- ASCLEPIX THERAPEUTICS, INC.1
- AVRYGEN CORPORATION1
- DEVACELL, INC.1
- INTEZYNE TECHNOLOGIES, LLC1
- KEYSTONE NANO, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2014 | Vault-CCL21 Nanocapsule for Lung Cancer2U44CA167593-02 | ROME, LEONARD HSRIVASTAVA, INDRESH K | PROTEIN SCIENCES CORPORATION, CT | $669,156 | ZCA1 |
| 2014 | Targeted nanoparticles to deliver a multimodal peptide to head and neck tumors1U43CA179506-01 | PANDEY, NIRANJAN B | ASCLEPIX THERAPEUTICS, INC., MD | $258,009 | ZCA1 |
| 2014 | Dual Targeted Nanoparticle therapy for Glioblastoma Multiforme1U43CA182921-01 | GOOMER, RANDAL SINGH | AVRYGEN CORPORATION, CA | $224,980 | ZCA1 |
| 2014 | Methioninase Loaded Nanoshells for Systemic Methionine Depletion Therapy1U43CA186114-01 | ORTAC, INANC | DEVACELL, INC., CA | $224,900 | ZCA1 |
| 2014 | Targeted siRNA NanoJackets for the Personalized Treatment of Breast Cancer1U43CA186118-01 | CARTER, CARLY JO | KEYSTONE NANO, INC., PA | $223,896 | ZCA1 |
| 2014 | Smart targeting nano-doxorubicin against breast cancer1U43CA184113-01 | LI, YUANPEI | LAMNOTHERAPEUTICS, INC., CA | $193,812 | ZCA1 |
| 2014 | Micellar Daunorubicin for the Treatment of Bone Cancer1U43CA179468-01 | SILL, KEVIN N | INTEZYNE TECHNOLOGIES, LLC, FL | $156,868 | ZCA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.